Cargando…

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

PURPOSE: Curative intended treatment is challenging in patients with relapsed or refractory acute myeloid leukemia (r/r AML) and associated with a dismal prognosis for long-term survival. Despite novel treatment options, the majority of patients are treated with chemotherapy-based regimens. Although...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mühleck, Regina, Scholl, Sebastian, Hilgendorf, Inken, Schrenk, Karin, Hammersen, Jakob, Frietsch, Jochen J., Fleischmann, Maximilian, Sayer, Herbert G., Glaser, Anita, Hochhaus, Andreas, Schnetzke, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349069/ https://www.ncbi.nlm.nih.gov/pubmed/34609595 http://dx.doi.org/10.1007/s00432-021-03821-1

Ejemplares similares

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
por: Tober, Romy, et al.
Publicado: (2022)

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient
por: Frietsch, Jochen J., et al.
Publicado: (2019)

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
por: Frietsch, Jochen J., et al.
Publicado: (2022)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

A 19-year-old patient with atypical chronic myeloid leukemia
por: Ernst, Philipp, et al.
Publicado: (2020)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
por: Voigt, Margarete, et al.
Publicado: (2021)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia
por: LUO, SHENG, et al.
Publicado: (2013)

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia
por: Fischer, Mike, et al.
Publicado: (2016)

Psychosocial distress in young adults surviving hematological malignancies: a pilot study
por: Wittwer, Andreas, et al.
Publicado: (2022)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Isolation of Hafnia paralvei co-harbouring bla(NDM-1) and bla(VIM-1) in a woman who underwent allogeneic hematopoietic stem cell transplantation
por: Appel, Tobias Manuel, et al.
Publicado: (2023)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
por: Scholl, Sebastian, et al.
Publicado: (2020)

Relapsed or primary refractory AML: moving past MEC and FLAG-ida
por: Koenig, Kristin, et al.
Publicado: (2020)

Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation
por: Pulewka, Kristin, et al.
Publicado: (2020)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
por: Iqbal, Nida, et al.
Publicado: (2014)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
por: Yılmaz Bengoa, Şebnem, et al.
Publicado: (2017)

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
por: Stadtmauer, Edward A, et al.
Publicado: (2009)

Treating second‐relapsed/refractory first‐relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
por: Merli, Pietro
Publicado: (2022)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2021)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
por: Lessi, Federica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9v063mpic4en1ckcglrdkgf1dp